DURHAM, N.C. – Data from the HIV Prevention Trials Network (HPTN) studies HPTN 083 and HPTN 084 helped provide important information for yesterday’s decision by the U.S. Food and Drug Administration (FDA) to approve ViiV Healthcare’s long-acting cabotegravir (CAB-LA) injections for the prevention of HIV.
DURHAM, N.C. – The HIV Prevention Trials Network (HPTN) announced today the launch of HPTN 094 (INTEGRA), a study to determine whether using mobile health units to deliver integrated health services for people with
SEATTLE, WA – JANUARY 26, 2021 – The proof-of-concept AMP studies demonstrated that a broadly neutralizing antibody (bnAb) called VRC01 was effective at preventing the acquisition of HIV strains that were sensitive to the bnAb. This was assessed by a laboratory test that measures a virus’ susceptibility to neutralization by an antibody. The two studies (HVTN 704/HPTN 085 and HVTN 703/HPTN 081) opened in April 2016 and successfully enrolled 4,623 participants.
DURHAM, N.C. – Drs. Myron S. Cohen and Wafaa M. El-Sadr, principal investigators of the HIV Prevention Trials Network (HPTN), in collaboration with FHI 360, have received a seven-year award from the U.S. National Institutes of Health as part of the next funding cycle (2020-2027) for the Network.
Both cabotegravir and oral TDF/FTC have high efficacy for PrEP among women in sub-Saharan Africa
Both cabotegravir and oral tenofovir/emtricitabine (TDF/FTC) have high efficacy for pre-exposure prophylaxis (PrEP)
Independent Data and Safety Monitoring Board Recommends Unblinding Study Participants
DURHAM, N.C. – Engaging disenfranchised men who have sex with men (MSM) living with HIV in the U.S. is possible, but the best way to help them achieve and maintain viral suppression is not yet known, according to findings from HPTN 078 being reported today at the 10th IAS Conference on HIV Science (IAS 2019) in Mexico City.
DURHAM, NC – Researchers today presented results from the HPTN 071 (PopART) study at the annual Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.
DURHAM, NC – Researchers from the HIV Prevention Trials Network (HPTN) today presented results from the HPTN 075 Study at the HIV Research for Prevention (HIVR4P) conference in Madrid, Spain. The study evaluated the feasibility of HIV prevention research among men who have sex with men (MSM) and transgender women (TGW) in three countries in sub-Saharan Africa. Findings from the study showed participants were at an alarming risk for getting HIV.
The HIV Prevention Trials Network (HPTN) congratulates the participants and researchers taking part in two important HIV prevention trials announcing results this week at the AIDS 2018 conference – the Sustainable East Africa Research in Community Health (SEARCH) study and the Botswana Combination Prevention Project (BCPP) study. Both studies were cluster-randomized, community-based trials conducted in sub-Saharan Africa that measured the impact of enhanced HIV services and the offer of universal treatment on HIV incidence.
DURHAM, N.C. – The HIV Prevention Trials Network (HPTN) today announced the initiation of HPTN 084, a Phase 3 double-blind safety and efficacy study of long-acting injectable cabotegravir (CAB) compared to a combination of daily oral tenofovir disoproxil fumarate 300 mg plus emtricitabine 200 mg (TDF/FTC).
DURHAM, N.C. – Study results released today by the HIV Prevention Trials Network (HPTN) show long-acting injectable cabotegravir (CAB LA) to be well tolerated by men and women and support the dosing schedule currently being used in a phase 3 HPTN study for HIV prevention. Analysis of HPTN 077 study data presented today at the 9th IAS Conference on HIV Science in Paris, France, supported further development of CAB LA for HIV prevention in men and women using 600mg (3 mL) injections every eight weeks with the first two injections given four weeks apart.